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Abstract.	
	
One	 of	 the	 widespread	 and	 prognostically	 unfavorable	 complications	 of	
cardiovascular	diseases	is	chronic	heart	failure,	where	an	important	role	is	given	
to	proinflammatory	cytokines	 in	 the	pathogenesis	of	 the	disease.	Polymorphic	
variants	of	the	gene	of	tumor	necrosis	factor-α	are	determinants	of	increased	risk	
in	 the	 development	 of	 chronic	 heart	 failure	 in	 patients	 with	 ischemic	 heart	
disease.	 Presence	 of	 allelic	 gene	 A	 and	 genotype	 A/A	 of	 polymorphic	 locus	 G-
308A,	the	gene	of	tumor	necrosis	factor-α	in	patients	with	ischemic	heart	disease	
and	concomitant	obesity	was	associated	with	chronic	heart	 failure	progressing	
and	development	of	systolic	dysfunction	of	the	left	ventricle.	
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Problem	statement	and	analysis	of	the	recent	research		
Chronic	heart	failure	(CHF)	is	one	of	the	common	and	prognostically	adverse	complications	
of	cardiovascular	system	diseases	[8].	
A	lot	of	researches	are	devoted	to	relation	of	genes	polymorphisms	with	the	most	common	
cardiovascular	diseases	(CVD)	and	activity	of	prescribed	treatment	for	this	patient	group.	Analysis	
of	 national	 and	 foreign	 literature	 shows	 that	 outstanding	 interest	 is	 attracted	 by	 the	 study	 of	
polymorphisms	of	genes	encoding	proteins	which	are	a	part	of	the	structure	of	enzymes,	hormones	
and	neurohormonal	 systems	 receptors	and	are	 involved	 in	 the	development	and	progression	of	
most	cardiovascular	diseases,	including	CHF[1,	5	6].	
Regarding	 CHF	 pathogenesis,	 the	 role	 of	 proinflammatory	 cytokines	 should	 not	 go	
unmentioned.	
The	 literature	 provides	 relatively	 few	 data	 on	 the	 association	 of	 genes	 polymorphisms	
encoding	proinflammatory	cytokines	with	CVD	development.	Researches	on	the	relation	of	these	
polymorphisms	with	 the	 risk	 of	CHF	 and	 character	 of	 its	progression	 in	patients	with	 coronary	
artery	disease	are	rare.	
Thus,	S.	N.	Shilov	et	al.	showed	in	their	work	that	polymorphic	variants	of	the	gene	of	tumor	
necrosis	 factor-α	 (TNF-α)	 (G-308A)	are	not	only	determinants	of	 increased	 risk	of	CHF	 in	patients	
with	 coronary	artery	disease	 (CAD),	but	also	are	associated	with	 the	 severity	and	nature	of	CHF	
course	 in	 these	patients	 [4].	No	associations	between	plasma	 concentrations	of	TNF-α	and	 gene	
polymorphism	of	TNF-α	(308	A	/	G,	238	A	/	G)	were	observed	in	another	study,	which	included	more	
than	266	patients	with	CHF	and	ejection	fraction	(EF)	below	40%	[11].	
Contradictory	data	obtained	are	probably	due	 to	 the	 lack	of	 large	 randomized	 studies	on	
this	 issue.	This	 again	 emphasizes	 the	need	 for	 further	 study	of	 genes	polymorphisms	 encoding	
proinflammatory	cytokines	and	their	influence	on	the	formation	and	progression	of	cardiovascular	
diseases	and	CHF.	
The	objective	of	the	research	was	to	evaluate	the	role	of	polymorphism	of	G-308A	gene	of	
tumor	necrosis	factor	-	α	as	a	possible	factor	in	the	progression	of	chronic	heart	failure	in	patients	
with	coronary	artery	disease	and	obesity.	
	
Materials	and	methods	of	the	research		
The	 study	 included	 a	 comprehensive	 examination	 of	 222	 patients	 with	 coronary	 artery	
disease	and	obesity	who	were	treated	in	the	cardiology	department	of	Kharkiv	City	Hospital	№27,	
which	 is	 the	 teaching	 health	 care	 facility	 of	 Department	 of	 Internal	 Medicine	 and	 Clinical	
Immunology	and	Allergology	№2	of	Kharkiv	National	Medical	University	of	Ministry	of	Health	of	
Ukraine.	Comparison	 group	 consisted	 of	 115	patients	with	 coronary	 artery	disease	with	normal	
body	 weight.	 The	 control	 group	 included	 35	 apparently	 healthy	 individuals.	 The	 groups	 were	
compared	by	age	and	sex.	The	study	excluded	patients	with	severe	concomitant	diseases	of	 the	
respiratory	and	digestive	systems,	kidneys	and	those	with	cancer.	
The	diagnosis	was	made	in	accordance	with	valid	orders	of	Ministry	of	Health	of	Ukraine.	
All	patients	underwent	general	clinical	and	instrumental	examination.	
Research	of	the	polymorphic	locus	of	G-308A	TNF-α	gene	was	performed	by	the	method	of	
polymerase	chain	reaction	with	results	electrophoretic	detection	using	reagent	kits	“SNP-Express”	
manufactured	by	Ltd.	“Liteh”	(Russia).	DNA	isolation	from	blood	was	performed	using	the	reagent	
"DNA	EXPRESS"	produced	by	SPC	 "Liteh"	 (Russia)	according	 to	 the	 instructions.	The	correctness	of	
the	frequency	distribution	of	genotypes	was	determined	by	the	correspondence	of	Hardy-Weinberg	
equilibrium	(pi2	+	2	pipj	+	pj2	=	1).	According	to	the	Helsinki	Declaration,	all	patients	were	informed	
about	the	clinical	trial	and	agreed	to	determine	investigated	gene	polymorphisms.	
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Statistical	 data	 processing	 was	 conducted	 using	 the	 package	 Statistica,	 version	 6.0.	 χ2	
Pearson	 and	 Fisher	 criteria	 was	 used	 to	 compare	 the	 distribution	 of	 genotypes	 and	 allele	
frequencies	between	groups.	The	odds	ratio	 (OR)	was	calculated	 to	determine	 the	relative	risk	of	
diseases.	OR	=	1	was	considered	as	no	association;	OR>1	considered	as	a	positive	association;	OR	
<1	was	considered	as	negative	allele	or	genotype	association	with	disease	(low	risk	of	the	disease).	
Credible	 interval	 (CI)	 is	an	 interval	of	values	within	which	OR	prognostic	value	of	 is	found	with	a	
probability	of	95%.	Statistically	significant	differences	were	considered	at	p<0.05.	
	
Results	of	the	research	and	their	discussion		
The	 impact	of	polymorphic	 locus	G-308A	TNF-α	gene	on	 the	CHF	progression	 in	patients	
with	coronary	artery	disease	and	obesity	was	studied.	The	results	are	presented	in	Table	1.	
In	patients	with	coronary	artery	disease	and	obesity	CHF	progression	from	FC	I	to	FC	II	was	
characterized	by	increased	frequency	of	polymorphic	locus	A	allele	G-308A	TNF-α	gene	by	10.92%	
and	A/A	 genotype	by	 11.05%	 (34%	versus	 44.	 92%	and	 22%	versus	 33.05%)	and	a	decrease	 in	 the	
frequency	of	G	allele	by	10.92%	and	G/G	genotype	by	10.33%	 (55.08%	vs	66%	and	40%	vs.	29.67%).	
CHF	progression	from	FC	II	to	FC	III-IV	was	characterized	by	a	decrease	by	10.37%	detection	rate	of	
G/G	genotype	(40%	vs.	29.63%)	(p<0.05).	CHF	progression	from	FC	I	to	FC	III-IV	was	characterized	by	
improbable	 increase	 in	 frequency	 of	 A	 allele	 and	 A/A	 genotype	 (34%	 versus	 40.74%	 and	 27.78%	
against	22%)	and	 from	FC	 II	 to	FC	 III-IV	by	 improbable	decrease	 in	 frequency	of	A	allele	and	A/A	
genotype	(44.92%	versus	40.74%	and	33.05%	against	27.78%)	(p>0.05).	Increase	in	FC	of	CHF	showed	
no	connection	with	G/A	genotype.	
	
Table	1	
The	frequency	of	alleles	and	genotypes	of	polymorphic	loci	G-308A	of	TNF-α	gene	
according	to	FC	of	CHF	in	patients	with	coronary	artery	disease	and	obesity	
Genetic	markers		 Subgroup	1	
FC	I	of	CHF	
(N	=	50)	
Subgroup	2	
FC	II	of	CHF	
(N	=	118)	
Subgroup	3	
FC	III-IV	of	CHF	
(N	=	54)	
A	Allele		 17	(34	%)	 53	(44.92	%)*	 22	(40.74	%)	
G	Allele		 33	(66	%)	 65	(55.08	%)*	 32	(59.25	%)	
G/A	Genotype	 19	(38	%)	 44	(37.28	%)	 23	(42.59	%)	
A/A	Genotype	 11	(22	%)	 39	(33.05	%)*	 15	(27.78	%)	
G/G	Genotype	 20	(40	%)	 35	(29.67	%)*	 16	(29.63	%)*	
Note.	*	-	the	probability	of	differences	with	subgroup	1	(p<0.05).	
	
Indicated	dynamics	 can	be	 explained	by	 the	 fact	 that	A	 allele	 carriership,	 as	 it	has	been	
proven,	is	associated	with	higher	levels	of	TNF-α,	compared	with	homozygotes	for	G	allele	[16].	The	
reasons	for	increase	in	the	level	of	circulating	cytokines	in	case	of	CHF	are	not	completely	studied,	
but	 increased	 expression	 of	 cytokines	 in	 the	 myocardium	 was	 found	 at	 the	 later	 stages	 of	 the	
disease	[2,	3,	7].	Myocardial	contribution	of	immunopeptides	products	to	increase	in	cytokines	level	
in	serum	is	limited	due	to	poor	diffusion	of	cytokines	in	coronary	blood	flow.	The	increase	in	CHF	
cytokine	 aggression	 is	 supposed	 to	 be	 caused	 by	 systemic	 tissue	 hypoxia	 determining	 systemic	
inflammation	 development	 [10].	 This	 cytokines	 dynamic	 suggests	 exhaustion	 of	 retention	
mechanisms	of	cachexia.	
The	distribution	of	frequencies	of	alleles	and	genotypes	of	polymorphic	loci	G-308A	TNF-α	
gene	 depending	 on	 LVEF	 in	 patients	 with	 CHF	 that	 occurred	 on	 the	 background	 of	 CHD	 with	
concomitant	obesity	are	presented	in	Table	2.	
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A	allele	carriership	(56	(46.28%)	versus	34	(33.66%))	was	observed	significantly	more	often	by	
12.62%	 in	patients	with	coronary	artery	disease	and	obesity	with	EF<45%	and	allele	G	carriership	
(65	 (53.72	%)	versus	66	 (66.34%))	was	observed	 less	often	compared	with	patients	whose	ejection	
fraction	was	higher	than	45%	(p<0.05).	A	allele	in	patients	with	LV	systolic	dysfunction	was	almost	
equally	detected	in	homozygous	and	heterozygous	forms	-	44	(36.37%)	and	47	(38.84%),	respectively.	
However,	 heterozygous	 genotype	 dominated	 (32	 (32.68%))	 in	 patients	 with	 preserved	 ability	
myocardial	 contraction	 compared	 to	 homozygous	 (22	 (21.78%)).	 Comparing	 the	 distribution	 of	
genotypes	 in	 subgroups	 it	 should	 be	 noted	 that	 A/A	 genotype	 was	 detected	 in	 patients	 with	
coronary	artery	disease	and	obesity	with	systolic	dysfunction	by	14.59%	more	often	than	in	patients	
with	EF>	45%	(44	(36.37%)	versus	22	(21.78%)),	and	G/G	genotype	was	observed	less	often	by	20.75%	
(30	(24.79%)	versus	46	(45.54%))	(p<0.05).	
	
Table	2	
The	frequency	of	alleles	and	genotypes	of	polymorphic	loci	G-308A	TNF-α	gene	depending	
on	LVEF	in	patients	with	coronary	artery	disease	and	obesity	
Genetic	markers		 Subgroup	1	
EF>45%	
(N	=	101)		
	
Subgroup	2		
EF<45%	
(N	=	121)	
	
А	Allele		 34	(33.66	%)	 56	(46.28	%)*	
G	Allele	 66	(66.34	%)	 65	(53.72	%)*	
G/A	Genotype	 32	(32.68	%)	 47	(38.84	%)	
A/A	Genotype	 22	(21.78	%)	 44	(36.37	%)*	
G/G	Genotype	 46	(45.54	%)	 	30	(24.79	%)*	
Note.	*	-	the	probabilit	of	differences	between	subgroups	(p<0.05).	
	
Thus,	the	formation	of	systolic	dysfunction	in	patients	with	CHF	on	the	background	of	CHD	
in	case	of	combined	course	and	obesity	is	associated	with	A	allele	and	A/A	genotype	of	TNF-α	gene	
(G-308A).	
According	to	the	literature,	-308A	allele	is	associated	with	a	6-7-fold	increase	in	the	level	of	
gene	 transcription	 of	 TNF-α	 compared	 to	 the	 -308G	 allele,	 which	 has	 a	 protective	 value	 for	 the	
clinical	course	of	the	disease	[13,	14,	17].	As	a	result,	more	clear	manifestation	of	their	biomedical	
effects	 (pro-inflammatory	 and	 cytotoxic	 effects,	 endothelial	 dysfunction,	 activating	 hemostasis	
system,	induce	apoptosis,	etc.)	may	be	expected	in	patients	with	high-performance	-308A	allele	of	
TNF-α	gene	[9,	12,	15].	
	
Conclusions		
A	 allele	 and	 A/A	 genotype	 of	 polymorphic	 locus	 G-308A	 TNF-α	 gene	 in	 patients	 with	
coronary	 artery	 disease	 with	 concomitant	 obesity	 was	 associated	 with	 progression	 of	 CHF,	 the	
formation	of	LV	systolic	dysfunction.	
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